Clinical Trials on Plasma Cell Disorders

Total 163779 results

University of Arkansas
University of Iowa

Not yet recruiting

High Dose Ascorbic Acid (HDAA) in Patients With Plasma Cell Disorders

Plasma Cell Disorder
Jonsson Comprehensive Cancer Center
Novartis Pharmaceuticals

Withdrawn

TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma (NYSCT MM)

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | HLA-A*0201 Positive Cells Present | NY-ESO-1 Positive Tumor Cells Present

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Filanesib and Carfilzomib in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Plasma Cell Leukemia

United States
Becton, Dickinson and Company

Completed

Evaluation of the Plasma Cell Disorders Panel on the BD FACSLyric™ Flow Cytometer

Plasma Cell Disorder

Switzerland, Spain, United Kingdom, United States, Portugal
City of Hope Medical Center
National Cancer Institute (NCI)

Withdrawn

Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients With High-Risk Multiple Myeloma

Plasma Cell Myeloma | Plasma Cell Leukemia in Remission

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma

Refractory Plasma Cell Myeloma | Plasmacytoma | Recurrent Plasma Cell Myeloma | Plasma Cell Leukemia

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Bortezomib, Melphalan, and Total-Body Irradiation Before Stem Cell Transplant in Treating Patients With Multiple Myeloma

Refractory Plasma Cell Myeloma | DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma

United States
National Cancer Institute (NCI)

Completed

Vismodegib After Stem Cell Transplant in Treating Patients With High-Risk First Remission or Relapsed Multiple Myeloma

Refractory Plasma Cell Myeloma | DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma

United States
Albert Einstein College of Medicine
National Cancer Institute (NCI)

Terminated

Desipramine Hydrochloride and Filgrastim For Stem Cell Mobilization in Patients With Multiple Myeloma Undergoing Stem Cell Transplant

Refractory Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma | DS (Durie/Salmon) Stage I Plasma Cell Myeloma

United States
Albert Einstein College of Medicine
National Cancer Institute (NCI)

Completed

Busulfan, Melphalan, and Bortezomib Before First-Line Stem Cell Transplant in Treating Patients With Multiple Myeloma

Refractory Plasma Cell Myeloma | DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Lenalidomide, Dexamethasone, and Clarithromycin in Treating Patients Who Have Undergone Stem Cell Transplant for Multiple Myeloma

Refractory Plasma Cell Myeloma | DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma

United States
Emory University
National Cancer Institute (NCI); Merck Sharp & Dohme LLC; National Institutes...

Completed

Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | ISS Stage III Plasma Cell Myeloma | ISS Stage II Plasma Cell Myeloma | ISS Stage I Plasma Cell Myeloma

United States
IRCCS Centro di Riferimento Oncologico della Basilicata
Celgene Corporation

Completed

Lenalidomide and Dexamethasone in Primary Plasma Cell Leukemia

Primary Plasma Cell Leukemia

Italy
Mayo Clinic
National Cancer Institute (NCI)

Completed

Carfilzomib and Melphalan Before Stem Cell Transplant in Treating Patients With Multiple Myeloma

Refractory Plasma Cell Myeloma | DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma

United States
National Cancer Institute (NCI)

Withdrawn

RO4929097 After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma

Refractory Plasma Cell Myeloma | DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma

United States
Roswell Park Cancer Institute
Celgene

Active, not recruiting

SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy

Plasma Cell Myeloma | Partial Response of Multiple Myeloma or Plasma Cell Leukemia

United States
National Cancer Institute (NCI)

Completed

FR901228 in Treating Patients With Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma

United States
Heidelberg Pharma AG

Recruiting

Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma

Multiple Myeloma | Plasma Cell Disorder

United States, Germany, Poland, Hungary
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma

DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma

United States
National Cancer Institute (NCI)

Completed

Bortezomib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Previously Untreated Symptomatic Multiple Myeloma

DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Bortezomib and Vorinostat in Treating Patients With Multiple Myeloma Who Have Undergone Autologous Stem Cell Transplant

DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Plasma Cell Leukemia | Loss of Chromosome 17p | Autologous Hematopoietic Stem Cell Transplant Recipient

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Panobinostat and Carfilzomib in Treating Participants With Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Non-Secretory Plasma Cell Myeloma | Plasmacytosis

United States
Ohio State University Comprehensive Cancer Center
National Cancer Institute (NCI)

Withdrawn

Study of Personalized Melphalan Dosing in the Setting of Autologous Transplant

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Hematopoietic Cell Transplantation Recipient

United States
Mayo Clinic

Recruiting

Genetically Engineered Cells (MUC1-Activated T-Cells) for the Treatment of MUC1 Positive Recurrent or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Emory University
National Cancer Institute (NCI)

Recruiting

Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Not yet recruiting

²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma

Plasma Cell Myeloma | Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
M.D. Anderson Cancer Center
Takeda

Active, not recruiting

Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
OHSU Knight Cancer Institute
Sanofi; Oregon Health and Science University

Active, not recruiting

Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
National Cancer Institute (NCI)

Withdrawn

Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Ixazomib Citrate, Pomalidomide, Dexamethasone, Stem Cell Transplant in Treating Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
University of California, San Francisco
Janssen Pharmaceuticals; Multiple Myeloma Research Foundation

Terminated

Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refractory Multiple Myeloma Previously Treated With Daratumumab

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Abdullah Khan

Terminated

Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
University of Washington
National Cancer Institute (NCI); SecuraBio

Terminated

Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Mayo Clinic
National Cancer Institute (NCI); Novartis Pharmaceuticals

Completed

Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Carfilzomib, Bendamustine Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
OHSU Knight Cancer Institute
Oregon Health and Science University

Completed

Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma

Recurrent Plasma Cell Myeloma | Plasma Cell Leukemia

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Pomalidomide or Lenalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Roswell Park Cancer Institute

Recruiting

Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma

Plasma Cell Myeloma | Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Smoldering Plasma Cell Myeloma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Mayo Clinic

Completed

Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma

Plasma Cell Myeloma | Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Roswell Park Cancer Institute
Bristol-Myers Squibb

Active, not recruiting

Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma Resistant to Chemotherapy

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Fred Hutchinson Cancer Center
The Leukemia and Lymphoma Society; Juno Therapeutics, Inc., a Bristol-Myers...

Terminated

BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Metformin, Nelfinavir, and Bortezomib in Treating Patients With Relapsed and/or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Emory University
National Cancer Institute (NCI); National Institutes of Health (NIH); Millennium... and other collaborators

Active, not recruiting

Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
National Cancer Institute (NCI)

Completed

Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

Canada
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Lenalidomide, Thalidomide and Dexamethasone in Treating Participants With Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

SMAC Mimetic LCL161 Alone or With Cyclophosphamide in Treating Patients With Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Withdrawn

Simvastatin in Overcoming Chemotherapy Resistance in Patients With Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
OHSU Knight Cancer Institute
National Cancer Institute (NCI)

Completed

Hydroxychloroquine, Cyclophosphamide, Dexamethasone, and Sirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States

Clinical Trials on Plasma Cell Disorders

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Albania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations